02997nas a2200397 4500000000100000008004100001260000900042653003000051653002500081653001200106653001200118653001900130653002600149653001400175653001400189653003100203653001500234653001700249653001800266653001800284653001900302653003100321653002000352653001000372100001500382700001200397700001300409700001400422700001300436245011800449856007400567300001100641490000600652520192700658022001402585 2013 d c201310aAdministration, Cutaneous10aAnalysis of Variance10aAnimals10aDapsone10aDrug Stability10aElectric Conductivity10aEmulsions10aEpidermis10aHydrogen-Ion Concentration10aMyristates10aNanomedicine10aNanoparticles10aParticle Size10aPyrrolidinones10aReproducibility of Results10aSkin Absorption10aSwine1 aBorges VRA1 aSimon A1 aSena ARC1 aCabral LM1 aSousa VP00aNanoemulsion containing dapsone for topical administration: a study of in vitro release and epidermal permeation. uhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572825/pdf/ijn-8-535.pdf a535-440 v83 a

BACKGROUND: Topical administration of dapsone can be an alternative route for treatment of leprosy and can also provide new therapeutic applications for an established drug. However, the physicochemical properties of dapsone make it difficult to incorporate into conventional formulations. The current study was directed toward developing a stable nanoemulsion that contains dapsone which can be adapted for topical use.

METHODS: Nanoemulsions were prepared using isopropyl myristate or n-methyl-pyrrolidone as the oil phase, and characterized according to their mean droplet size, conductivity, refractive index, pH, drug content, and stability. The in vitro release of dapsone and its ability to permeate the epidermis were also evaluated.

RESULTS: Physicochemical characterization demonstrated that nanosystems were formed, which had a uniform droplet distribution and a pH compatible with the skin surface. Use of n-methyl-pyrrolidone provided a greater nanoemulsion region and higher solubilization of dapsone, and increased the in vitro release rate when compared with a nanoemulsion prepared using isopropyl myristate. However, use of isopropyl myristate promoted an increase in in vitro epidermal permeation that followed the Higuchi model. This demonstrates the ability of a nanosystem to influence permeation of dapsone through the skin barrier. Furthermore, the nanoemulsions developed and evaluated here had ideal physicochemical stability over a 3-month period.

CONCLUSION: Incorporation of dapsone into a nanoemulsion may be a promising system for enabling topical delivery of dapsone, while minimizing skin permeation, for the treatment of acne. The method developed here used isopropyl myristate as the oil phase, and promoted permeation of dapsone through the skin barrier for the treatment of leprosy upon use of n-methyl-pyrrolidone as the oil phase.

 a1178-2013